EP1957088B1 - Viscosupplementation with algal polysaccharides in the treatment of arthritis - Google Patents
Viscosupplementation with algal polysaccharides in the treatment of arthritis Download PDFInfo
- Publication number
- EP1957088B1 EP1957088B1 EP06821630A EP06821630A EP1957088B1 EP 1957088 B1 EP1957088 B1 EP 1957088B1 EP 06821630 A EP06821630 A EP 06821630A EP 06821630 A EP06821630 A EP 06821630A EP 1957088 B1 EP1957088 B1 EP 1957088B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- polysaccharide
- joint
- composition
- arthritis
- viscosupplement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Not-in-force
Links
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 91
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 91
- 150000004676 glycans Chemical class 0.000 title claims abstract description 90
- 206010003246 arthritis Diseases 0.000 title claims abstract description 14
- 238000011282 treatment Methods 0.000 title description 9
- 239000000203 mixture Substances 0.000 claims abstract description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 208000012659 Joint disease Diseases 0.000 claims abstract description 7
- 239000007864 aqueous solution Substances 0.000 claims abstract description 6
- 230000002163 immunogen Effects 0.000 claims abstract description 4
- 210000003127 knee Anatomy 0.000 claims description 33
- 239000003932 viscosupplement Substances 0.000 claims description 21
- 241000206618 Porphyridium Species 0.000 claims description 16
- 201000008482 osteoarthritis Diseases 0.000 claims description 15
- 108010003272 Hyaluronate lyase Proteins 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 102000001974 Hyaluronidases Human genes 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 229960002773 hyaluronidase Drugs 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 239000000730 antalgic agent Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- -1 anesthetic Substances 0.000 claims description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 201000005569 Gout Diseases 0.000 claims description 4
- 239000003470 adrenal cortex hormone Substances 0.000 claims description 4
- 210000003423 ankle Anatomy 0.000 claims description 4
- 230000003266 anti-allergic effect Effects 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 claims description 4
- 230000007850 degeneration Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 210000001513 elbow Anatomy 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 239000003158 myorelaxant agent Substances 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- 210000002832 shoulder Anatomy 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 210000002517 zygapophyseal joint Anatomy 0.000 claims description 4
- 230000003444 anaesthetic effect Effects 0.000 claims description 3
- 230000001857 anti-mycotic effect Effects 0.000 claims description 3
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 3
- 239000002543 antimycotic Substances 0.000 claims description 3
- 210000001624 hip Anatomy 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 4
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 description 25
- 239000007924 injection Substances 0.000 description 25
- 229920002674 hyaluronan Polymers 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 229940099552 hyaluronan Drugs 0.000 description 14
- 210000001503 joint Anatomy 0.000 description 14
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 14
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 241001494479 Pecora Species 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 210000001179 synovial fluid Anatomy 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 210000000629 knee joint Anatomy 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241001302393 Porphyridium sp. Species 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 238000005461 lubrication Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 241000195493 Cryptophyta Species 0.000 description 3
- 241000219061 Rheum Species 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000005786 degenerative changes Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010007710 Cartilage injury Diseases 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000001520 comb Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001050 lubricating effect Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- 108010056594 Avian Proteins Proteins 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102100028965 Proteoglycan 4 Human genes 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 231100001032 irritation of the eye Toxicity 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 108010009030 lubricin Proteins 0.000 description 1
- 238000007433 macroscopic evaluation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 210000000426 patellar ligament Anatomy 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 238000001629 sign test Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004722 stifle Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Definitions
- the present invention relates to compositions comprising red algal polysaccharides of the genus Porphyridium for use as a viscosupplement in treating joints afflicted with arthritis or with diseases related to joint lubrication.
- Arthritis is chronic inflammation of the joint, accompanied by pain, swelling and limitation of movement in joints and connective tissue. It afflicts more than 40 million people in the United States.
- the most prevalent forms of arthritis are osteoarthritis and rheumatoid arthritis, both of them being progressive, degenerative diseases leading to varying degrees of disability.
- the cartilage and bone of the joint undergo destruction with the progress of the disease, followed by loss of mobility, and increased suffering caused, among others, by the rubbing of bone against bone.
- the therapies available at present, include palliative treatment, based on the use of analgesic or anti-inflammatory agents, and surgical therapy, comprising a partial or total joint replacement.
- the total replacement is used routinely for the knee, which is the most important joint usually afflicted by the disease. This is an expensive procedure that includes patient discomfort, possible serious post-operative morbidity, and risks associated with surgery involving opening up the joint.
- the replacement has also a drawback of limited durability, since the implanted prostheses last about 10-15 years.
- An alternative approach is viscosupplementation which is an injection into the joint of a biocompatible lubricant that reduces friction and pain.
- synovium produces a highly viscous lubricating fluid, consisting of high-molecular-weight substances, such as hyaluronan and lubricin.
- the highly viscous nature of the synovial fluid is important for normal joint function, since it provides a nearly frictionless interface for joint movement.
- a molecule of hyaluronan polysaccharide (3-5 ⁇ 10 6 daltons), consisting of monosaccharides N-acetyl glucosamine and glucuronic acid, binds many water molecules in its polyanionic structure, which is important for its mechanical properties.
- Hyaluronic acid is probably hydrolyzed by hyaluronidase enzymes, present in mammalian tissues.
- Another drawback of viscosupplements made of chicken combs is a possible allergic reaction induced in individuals allergic to avian proteins, feathers, and eggs.
- CA 2249103 describes chlamyhyaluronic acid a novel hyaluronic acid from green algae.
- US 2005/0196410 describes a seaweed extract for retarding inflammation.
- WO 01/82936 describes the use of fucoidin a polysaccharide from brown seaweed, in ameliorating arthritis Huheihel et al. [ J. Biochem. Biophys. Methods 50 (2002) 189-200 ] demonstrates antiviral activity of the polysaccharide from the red microalga Porphyridium sp.
- the polysaccharides of various species of red microalgae were found to be very stable in solution, even when exposed to a wide range of pH values and temperatures [ Geresh S., et al.: Biores.
- This invention provides a composition containing a polysaccharide from red microalga of the genus Porphyridium for use as a viscosupplement, wherein said algal polysaccharide is preferably in an aqueous solution in a concentration of 0.5 to 2 %w/w.
- the composition of the invention has viscosity in the range of 500 to 8,000 cP at room temperature, and is resistant to hyaluronidase ( in vitro ).
- the polysaccharides are prepared from algae of genus Porphyridium .
- composition according to the invention may further comprise analgesic agent, anti-inflammatory agent, antimicrobial agent, antiviral agent, anesthetic, muscle relaxant, salts, buffers, diluents, or a medicament needed for treating a concurrent disorder, such as antibiotic, corticoid, antiallergic, or antineoplastic.
- analgesic agent such as analgesic agent, anti-inflammatory agent, antimicrobial agent, antiviral agent, anesthetic, muscle relaxant, salts, buffers, diluents, or a medicament needed for treating a concurrent disorder, such as antibiotic, corticoid, antiallergic, or antineoplastic.
- This invention further provides use of an algal polysaccharide of the genus Porphyridium in treatment of arthritis and other disorders related to joint lubrication, preferably osteoarthritis, rheumatoid arthritis, gout, trauma, (age related) degeneration, said treatment comprising injecting said composition into a joint, which is chosen from knee, hip, shoulder, ankle, elbow, spinal facet joint, or knuckle.
- an algal polysaccharide of the genus Porphyridium in the preparation of a viscosupplement composition for treating arthritis or other disorders related to joint lubrication is also provided.
- This invention also relates to a kit comprising sterile equipment for injecting fluids into a joint, a viscosupplement composition comprising an algal polysaccharide of the genus Porphyridium and supplier's instructions.
- compositions containing polysaccharides of red microalgae belonging to the genera Porphyridium are stable in the mammalian synovial fluid, and exhibit superior properties as viscosupplements in the joints.
- Preliminary results have shown that rabbits knees treated with the polysaccharide showed less degenerative changes in the cartilage when compared with rabbits knees treated with available commercial means.
- compositions of this invention were injected to the knees of 6 rabbits, in which experimental osteoarthritis had been induced (12 joints in total), thus 6 joints for each composition, and the effects were examined in the dissected joints after sacrificing the animals at 12 weeks post-operatively.
- the degenerative changes were less marked in all the animals that had received the algal polysaccharide.
- hyaluronan as a natural lubricating polysaccharide, or as a viscosupplement
- another polysaccharide as far as this substitute polysaccharide is polyanionic, high-molecular-weight, non-toxic, and resistant to a hyaluronidase.
- the anions in said polyanionic polysaccharides can be provided by glucuronic acid, or by ester sulfate groups.
- Polysaccharides from red microalgae belonging to the genera Porphyridium was found by the inventors to be suitable viscosupplements, and the polysaccharide from Porphyridium is presented here as the embodiment of this invention.
- This invention provides a composition containing an algal polysaccharide of the genus Porphyridium for use as a viscosupplement.
- a composition of this invention is preferably an aqueous solution, containing said algal polysaccharide in a concentration of from 0.5 to 2% w/w, and has viscosity in the range from 500 to 8000 cP at room temperature.
- the composition of this invention comprises a polysaccharide from alga of genus Porphyridium, which is dissolved in a saline solution, and has a concentration from 0.5 to 2% w/w, and a viscosity of from 500 to 8,000 cP, preferably at room temperature, and is resistant to hyaluronidase in vitro.
- This invention also relates to the use of said algal polysaccharides in the preparation of compositions for treating arthritis and other joint disorders, preferably osteoarthritis, rheumatoid arthritis, gout, arthritis, trauma, (age related) degeneration, wherein said composition is preferably a non-immunogenic, non-toxic, water solution having a concentration of said polysaccharide from 0.5 to 2% w/w, and said joints are any one of knee, hip joint, shoulder, ankle, elbow, spinal facet joint, or knuckle.
- compositions according to this invention may comprise an analgesic agent, anti-inflammatory agent, antimicrobial agent, antiviral agent, muscle relaxant, salts, buffers, or diluents.
- Said composition may further contain a medicament needed for treating a concurrent disorder, said medicament being for example antibiotic, antimycotic, corticoid, antiallergic.
- the viscosupplement composition is injected to an afflicted joint, for example in volumes of from about 0.1 to about 5 ml.
- the algal polysaccharide may be supplied to the afflicted joint in a larger volume of less concentrated solution, or in a smaller volume of more concentrated solution. Water is removed from the joint more quickly than the polysaccharide, and this fact can be taken into consideration, when planning the regimen. In case of a more viscous preparation, a dilution by saline and injecting larger volume can be considered.
- the size of the treated joint is one of the factors to be considered, and volumes of synovial fluid, known to a skilled person, may be also taken into account.
- the viscosupplement can be supplied in one portion or repeatedly.
- synovial fluid from a knee inflicted by arthritis is removed by a sterile syringe, and 1 ml of 2 % solution of the polysaccharide of Porphyridium sp. in saline is injected into this knee, this treatment being optionally repeated.
- the red algal polysaccharides were found to have anti-inflammatory, antioxidant [ Matsui S. M. et al.: Biochem. Biotechnol. 104 (2003) 13-22 ; Tannin-Spitz T. et al.: J. Appl. Phycol. 17 (2005) 215-22 ], and emollient activities, and the polysaccharide of Porphyridium sp. was found, in addition to it, to inhibit Herpes simplex viruses types 1 and 2 and Varicella zoster virus in vitro, with no cytotoxic effects [ Arad S. et al.: Recent Advances in Marine Biotechnology: Biomaterials from Aquatic and Terrestrial Organisms. (2005) (In Press )].
- This invention provides also use of algal polysaccharides in the treatment of a joint disorder chosen from osteoarthritis, rheumatoid arthritis, gout, trauma, (age related) degeneration, or tumor, comprising i) preparing a composition containing an algal polysaccharide resistant to hyaluronidase; and ii) injecting said composition into an afflicted joint, for example in a volume of from about 0.1 to about 3 ml, either in one portion or repeatedly.
- Said joint is chosen from knee, hip, shoulder, ankle, elbow, spinal facet joint, or knuckle.
- Said composition contains an algal polysaccharide in an aqueous solution in a concentration of from about 0.5 to about 2% w/w, and has viscosity in the range of about 500 to about 8,000 cP at room temperature.
- the polysaccharide is resistant to hyaluronidase in vitro , and is isolated from an alga of genus Porphyridium.
- concurrent use of a component chosen from analgesic agent, anti-inflammatory agent, antimicrobial agent, antiviral agent, anesthetic, muscle relaxant, salts, buffers, or diluents is involved.
- a medicament needed for treating a concurrent disorder is used, said medicament being chosen from antibiotic, antimycotic, corticoid, antiallergic, or antineoplastic.
- Said composition is essentially non-immunogenic and non-toxic.
- This invention also relates to a kit comprising a sterile equipment for injecting fluids into joints, a viscosupplement composition according to this invention, and supplier's instructions.
- Porphyridium sp. (UTEX 637) was grown in an artificial sea water (ASW) medium under controlled conditions, and in a large-scale setup, as follows. A piece of slant was transferred aseptically to each sterile Erlenmeyer flask containing 100 ml of ASW. The Erlenmeyer flasks were maintained in a controlled growth room on shaker with light supplied from above by fluorescent lighting of about 90 ⁇ Em -2 s -1 intensity, at a temperature of 25 ⁇ 3°C. After 7-10 days, the volume of each Erlenmeyer flask was transferred to a glass column. The columns were maintained under light supplied from the side at an intensity of 150 ⁇ Em -2 s -1 .
- the cultures were mixed with air containing 1-3% CO 2 at a flow rate of 2 liters per minute. After 3-6 days when the culture had reached 20-50 ⁇ 10 6 cells/ml, the entire volume of each column was transferred to a polyethylene sleeve. Each sleeve was filled to a final volume of 3.0 liters of culture containing 5-8 ⁇ 10 6 cells/ml. The sleeves were maintained under light supplied from the side at an intensity of 150 ⁇ Em -2 s -1 . The cultures were mixed with air containing 1-3% CO 2 at a flow rate of 2 liters per minute. The logarithmic phase of growth was followed by the stationary phase during which the polysaccharide accumulated in the growth medium. After 15-20 days, the polysaccharide was harvested from the enriched medium.
- the cells of the red microalgae are encapsulated within a sulfated polysaccharide, the external part of which dissolves in the medium.
- a sulfated polysaccharide the external part of which dissolves in the medium.
- the entire volume of the culture in the sleeves, as obtained above, was transferred to a large vessel.
- the cells were separated from the supernatant using a continuous centrifugation (Cepa Z-41 20,000 rpm), and the supernatant was collected.
- the polysaccharide is treated further by using cross flow filtration technology for removing salts and concentrating the polysaccharide.
- the final product had > 0.9%, viscosity > 1400 cP.
- the concentration of the polysaccharides was determined by taking a sample of 0.5 ml of polysaccharide solution with 9.5 ml water. Typical preparation had 0.9%-1% w/w polysaccharide with phenol sulfuric acid according to Dubois M. et al. [Anal. Chem. 28 (1956) 341-354 ].
- Viscosity was measured using Brookfield Digital Viscometer, model DV-II. Sample of 10 ml polysaccharide was measured in spindle no. 25, speed of 30 rpm, and at room temperature.
- the polysaccharide has been tested for toxicity (irritation of the eyes) and was found to be safe for use on animals (Harlan Biotech Israel).
- An anterior cruciate ligament (ACL) resection animal model for the induction of experimental osteoarthritis in rabbits was used. Briefly, after anesthetization and preparation of two knees, the skin was incised longitudinally for approximately 3 cm medial to the patellar tendon. After opening the joint capsule, the ACL was resected macroscopically. Instability was confirmed manually by performing the anterior drawer sign test. The joint space was flushed with saline and closed with sutures. The animals received post-operative analgesics.
- Algal polysaccharide and a commercially available hyaluronan were used as viscosupplement in rabbit model.
- Algal polysaccharide 1% w/w in saline solution, pH 6.5-7.5 was prepared as described above, hyaluronan was obtained 1% w/w, both preparations were sterile.
- Six rabbits were treated as described above. Beginning one week after the resection ACL, intra-articular injections were given once a week for three consecutive weeks as follows: one knee was injected with hyaluronan preparation (0.1 cc), while the other knee was injected with algal polysaccharide (0.1 cc). Three rabbits were sacrificed at 6 weeks, the remaining animals were sacrificed after 12 weeks. The knee joints were dissected and subjected to histopathological examination according to the modified Mankin criteria [ Clinical Orthopedic Research 298 (1994) 296-304 ]. The degenerative changes were more marked in the knees treated with the control material.
- the study population comprised 22 healthy female Awassi sheep aged two years. Osteoarthritis was induced by performing a lateral menisectomy under general anesthesia in both stifle joints of each animal. The sheep were allowed to roam free during the first 16 weeks after the surgery, with free access to food and water. By 16 weeks, all the animals walked with a limp. At 16 weeks, the sheep were given intraarticular injections of a microalgal polysaccharide or Arthrease according to the following protocol: Table 2.
- each joint was accessed by a median approach. The procedure was performed under general anesthesia in an operating room. Following the injections, the sheep were returned to the farm until the end of the study, which lasted for a total of 36 weeks. At the end of that time, the animals were killed, and their knees were dissected. Upon dissection, the knees were assessed by a cartilage-damage grading system, which grades articular cartilage from 0 (normal cartilage), through various stages of damage to 5 (loss of cartilage and exposed bone). After dissection and gross evaluation of the knees, the joint surfaces were decalcified, and two slides were prepared from each joint surface. The slides were stained with hematoxylin & eosin and graded according to an adapted Mankin score, which evaluates cartilage damage.
- the overall score for the knees treated with polysaccharide was lower (i.e., better) than for the knees treated with Arthrease, although no statistically significant differences were found.
- the evaluation was repeated with the exclusion of the specimens graded as grades 4 and 5. Unmatched analysis showed that the overall score for the knees treated with polysaccharide was lower (i.e., better) than for knees treated with Arthrease, although no statistically significant differences were found.
- the Porphyridium sp polysaccharide was resistant toward hyaluronidase in vitro. 1ml of 0.02% wt% substrate (either hyaluronic acid or algal polysaccharide) in 0.1M phosphate buffer containing 0.15M sodium chloride, pH 5.45, was placed into Oswald viscometer, in bath thermostat at 37°C. After 5 min of incubation, the mammalian hyluronidase (Sigma, H-4272) in the same buffer solution (concentration 0.2 mg/ml) was added into the viscometer, and the count of reaction time started. The time of outflow of the reaction mixture from reservoir of viscometer was determined for reaction times 4, 8, 15, 20 and 30 min. Whereas the viscosity of hyaluronic acid was continually decreasing, the viscosity of the algal polysaccharide remained essentially unchanged.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Lubricants (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
- The present invention relates to compositions comprising red algal polysaccharides of the genus Porphyridium for use as a viscosupplement in treating joints afflicted with arthritis or with diseases related to joint lubrication.
- Arthritis is chronic inflammation of the joint, accompanied by pain, swelling and limitation of movement in joints and connective tissue. It afflicts more than 40 million people in the United States. The most prevalent forms of arthritis are osteoarthritis and rheumatoid arthritis, both of them being progressive, degenerative diseases leading to varying degrees of disability. The cartilage and bone of the joint undergo destruction with the progress of the disease, followed by loss of mobility, and increased suffering caused, among others, by the rubbing of bone against bone.
- The therapies, available at present, include palliative treatment, based on the use of analgesic or anti-inflammatory agents, and surgical therapy, comprising a partial or total joint replacement. The total replacement is used routinely for the knee, which is the most important joint usually afflicted by the disease. This is an expensive procedure that includes patient discomfort, possible serious post-operative morbidity, and risks associated with surgery involving opening up the joint. The replacement has also a drawback of limited durability, since the implanted prostheses last about 10-15 years. An alternative approach is viscosupplementation which is an injection into the joint of a biocompatible lubricant that reduces friction and pain. The rationale for this approach has its origin in the physiology of joints, where the synovium produces a highly viscous lubricating fluid, consisting of high-molecular-weight substances, such as hyaluronan and lubricin. The highly viscous nature of the synovial fluid is important for normal joint function, since it provides a nearly frictionless interface for joint movement. A molecule of hyaluronan polysaccharide (3-5×106 daltons), consisting of monosaccharides N-acetyl glucosamine and glucuronic acid, binds many water molecules in its polyanionic structure, which is important for its mechanical properties. Several viscosupplementation products, based on hyaluronan preparations, have become available in the past few years, aiming to restore the composition of the affected synovial fluid in patients with osteoarthritis, thereby providing these patients with relief from their symptoms. Hyaluronan for these viscosupplements has been usually produced from chicken combs (Synvisc™) or synthetically (Arthrease™).
- Several studies have been conducted to evaluate the efficacy of exogenous hyaluronan in the treatment of osteoarthritis, and conflicting results have been reported. In a trial of 91 patients, viscosupplementation of hyaluronan did not have a significantly better effect than placebo in the treatment of osteoarthritis [Henderson K., et al.: Ann. Rheum. Dis. 53 (1994) 529-34]. In another trial, a subgroup of patients older than 60 years with more severe symptoms did report beneficial effects from viscosupplementation therapy [Wen D.Y.: Am. Fam. Physician 62 (2000) 565-70]. A meta-analysis compiling the findings of eight different studies in a total of 971 patients indicated that hyaluronan treatment was superior to a placebo in alleviating osteoarthritis-related symptoms [George E.: Ann. Rheum. Dis. 57 (1998) 637-40]. Limitations of the beneficial effects of hyaluronan injection may result from the limited stability of hyaluronan in synovial fluid. For example, the half-life of hyaluronate in sheep joint was reported to be less than 24 hours [Fraser J.R.E., et al.: Semin. Arthritis Rheum. 22(6S) (1993) 9-17]. Hyaluronic acid is probably hydrolyzed by hyaluronidase enzymes, present in mammalian tissues. Another drawback of viscosupplements made of chicken combs is a possible allergic reaction induced in individuals allergic to avian proteins, feathers, and eggs.
- The availability of an efficient viscosupplementation therapy would provide relief to patients afflicted by disorders related to degenerative joint disease with joint lubrication, and in more serious cases, it would postpone the need for surgical intervention and reduce the number of operations performed. It is therefore an object of this invention to provide a viscosupplement composition exhibiting high stability in the synovial fluid.
-
CA 2249103 describes chlamyhyaluronic acid a novel hyaluronic acid from green algae.US 2005/0196410 describes a seaweed extract for retarding inflammation.WO 01/82936 - This invention provides a composition containing a polysaccharide from red microalga of the genus Porphyridium for use as a viscosupplement, wherein said algal polysaccharide is preferably in an aqueous solution in a concentration of 0.5 to 2 %w/w. The composition of the invention has viscosity in the range of 500 to 8,000 cP at room temperature, and is resistant to hyaluronidase (in vitro). The polysaccharides are prepared from algae of genus Porphyridium. The composition according to the invention may further comprise analgesic agent, anti-inflammatory agent, antimicrobial agent, antiviral agent, anesthetic, muscle relaxant, salts, buffers, diluents, or a medicament needed for treating a concurrent disorder, such as antibiotic, corticoid, antiallergic, or antineoplastic.
- This invention further provides use of an algal polysaccharide of the genus Porphyridium in treatment of arthritis and other disorders related to joint lubrication, preferably osteoarthritis, rheumatoid arthritis, gout, trauma, (age related) degeneration, said treatment comprising injecting said composition into a joint, which is chosen from knee, hip, shoulder, ankle, elbow, spinal facet joint, or knuckle. The use of an algal polysaccharide of the genus Porphyridium in the preparation of a viscosupplement composition for treating arthritis or other disorders related to joint lubrication is also provided.
- This invention also relates to a kit comprising sterile equipment for injecting fluids into a joint, a viscosupplement composition comprising an algal polysaccharide of the genus Porphyridium and supplier's instructions.
- It has now been found that compositions containing polysaccharides of red microalgae belonging to the genera Porphyridium are stable in the mammalian synovial fluid, and exhibit superior properties as viscosupplements in the joints. Preliminary results have shown that rabbits knees treated with the polysaccharide showed less degenerative changes in the cartilage when compared with rabbits knees treated with available commercial means.
- A solution of algal polysaccharide was separated from Porphyridium sp. culture by removing the cells by centrifugation, and then was treated for removal of salts. In concentrations of 0.5% to 2% w/w, water solution of the product had typically viscosity between 500 to 8,000 cP. Liquid compositions were prepared by concentrating the algal polysaccharide from cultures to 0.5-2% in saline solution. The polysaccharide was tested for toxicity and was found to be safe for use on animals (Harlan Biotech Israel). To compare the effects of a composition of this invention and a composition of the prior art, a composition containing either algal polysaccharide or hyaluronan were injected to the knees of 6 rabbits, in which experimental osteoarthritis had been induced (12 joints in total), thus 6 joints for each composition, and the effects were examined in the dissected joints after sacrificing the animals at 12 weeks post-operatively. The degenerative changes were less marked in all the animals that had received the algal polysaccharide.
- The validation of the results obtained with the pilot study has been initiated with a follow up study on sheep. Briefly, experimental osteoarthritis was induced by lateral menisectomy in both stifle joins of 24 female sheep of same age and stock. After the operation the sheep were free to ambulate for 16 weeks in order to develop osteoarthritis. After 16 weeks the animals were divided into three groups and each group received a treatment regimen including the polysaccharide composition in one knee and a commercial available hyluronan product - Arthrease - in the opposite knee, which will serve as the control group as shown in Table 1.
Table 1. Study protocol Group number Right knee Left knee 1 (8 animals) Polysaccharide single injection Saline 2 (7 animals) Polysaccharide single injection Arthrease single injection
once a week for three weeks3 (7 animals) Polysaccharide single injection Arthrease single injection
once a week for three weeksonce a week for three weeks - After 12 additional weeks the sheep were sacrificed and the knees dissected. The knees were subjected to histopathological examination and the efficacy of the polysaccharide was established.
- The algal polysaccharide of Porphyridium in physiological solution and autoclaved, was not degraded by hyluronidase in vitro, as indicated by viscosity measurements.
- Thus, without being committed to any theory, it is suggested, and it is a part of this invention, that hyaluronan as a natural lubricating polysaccharide, or as a viscosupplement, can be replaced by another polysaccharide as far as this substitute polysaccharide is polyanionic, high-molecular-weight, non-toxic, and resistant to a hyaluronidase. The anions in said polyanionic polysaccharides can be provided by glucuronic acid, or by ester sulfate groups. Polysaccharides from red microalgae belonging to the genera Porphyridium was found by the inventors to be suitable viscosupplements, and the polysaccharide from Porphyridium is presented here as the embodiment of this invention.
- This invention provides a composition containing an algal polysaccharide of the genus Porphyridium for use as a viscosupplement. A composition of this invention is preferably an aqueous solution, containing said algal polysaccharide in a concentration of from 0.5 to 2% w/w, and has viscosity in the range from 500 to 8000 cP at room temperature. In a preferred embodiment, the composition of this invention comprises a polysaccharide from alga of genus Porphyridium, which is dissolved in a saline solution, and has a concentration from 0.5 to 2% w/w, and a viscosity of from 500 to 8,000 cP, preferably at room temperature, and is resistant to hyaluronidase in vitro.
- This invention also relates to the use of said algal polysaccharides in the preparation of compositions for treating arthritis and other joint disorders, preferably osteoarthritis, rheumatoid arthritis, gout, arthritis, trauma, (age related) degeneration, wherein said composition is preferably a non-immunogenic, non-toxic, water solution having a concentration of said polysaccharide from 0.5 to 2% w/w, and said joints are any one of knee, hip joint, shoulder, ankle, elbow, spinal facet joint, or knuckle.
- Compositions according to this invention may comprise an analgesic agent, anti-inflammatory agent, antimicrobial agent, antiviral agent, muscle relaxant, salts, buffers, or diluents. Said composition may further contain a medicament needed for treating a concurrent disorder, said medicament being for example antibiotic, antimycotic, corticoid, antiallergic.
- In a preferred embodiment of this invention, the viscosupplement composition is injected to an afflicted joint, for example in volumes of from about 0.1 to about 5 ml. The algal polysaccharide may be supplied to the afflicted joint in a larger volume of less concentrated solution, or in a smaller volume of more concentrated solution. Water is removed from the joint more quickly than the polysaccharide, and this fact can be taken into consideration, when planning the regimen. In case of a more viscous preparation, a dilution by saline and injecting larger volume can be considered. When determining the size of the injected volume, the size of the treated joint is one of the factors to be considered, and volumes of synovial fluid, known to a skilled person, may be also taken into account. The viscosupplement can be supplied in one portion or repeatedly. In one embodiment, synovial fluid from a knee inflicted by arthritis is removed by a sterile syringe, and 1 ml of 2 % solution of the polysaccharide of Porphyridium sp. in saline is injected into this knee, this treatment being optionally repeated.
- The red algal polysaccharides were found to have anti-inflammatory, antioxidant [Matsui S. M. et al.: Biochem. Biotechnol. 104 (2003) 13-22; Tannin-Spitz T. et al.: J. Appl. Phycol. 17 (2005) 215-22], and emollient activities, and the polysaccharide of Porphyridium sp. was found, in addition to it, to inhibit Herpes simplex viruses types 1 and 2 and Varicella zoster virus in vitro, with no cytotoxic effects [Arad S. et al.: Recent Advances in Marine Biotechnology: Biomaterials from Aquatic and Terrestrial Organisms. (2005) (In Press)]. These properties may further enhance beneficial properties of algal polysaccharides in their use as viscosupplements in treating joint disorders. This invention provides also use of algal polysaccharides in the treatment of a joint disorder chosen from osteoarthritis, rheumatoid arthritis, gout, trauma, (age related) degeneration, or tumor, comprising i) preparing a composition containing an algal polysaccharide resistant to hyaluronidase; and ii) injecting said composition into an afflicted joint, for example in a volume of from about 0.1 to about 3 ml, either in one portion or repeatedly. Said joint is chosen from knee, hip, shoulder, ankle, elbow, spinal facet joint, or knuckle. Said composition contains an algal polysaccharide in an aqueous solution in a concentration of from about 0.5 to about 2% w/w, and has viscosity in the range of about 500 to about 8,000 cP at room temperature. The polysaccharide is resistant to hyaluronidase in vitro, and is isolated from an alga of genus Porphyridium. In some embodiments of the use of algal polysaccharides in the treatment of joint disorders according to this invention, concurrent use of a component chosen from analgesic agent, anti-inflammatory agent, antimicrobial agent, antiviral agent, anesthetic, muscle relaxant, salts, buffers, or diluents is involved. In other embodiments, a medicament needed for treating a concurrent disorder is used, said medicament being chosen from antibiotic, antimycotic, corticoid, antiallergic, or antineoplastic. Said composition is essentially non-immunogenic and non-toxic.
- This invention also relates to a kit comprising a sterile equipment for injecting fluids into joints, a viscosupplement composition according to this invention, and supplier's instructions.
- The invention will be further described and illustrated in the following examples.
- Porphyridium sp. (UTEX 637) was grown in an artificial sea water (ASW) medium under controlled conditions, and in a large-scale setup, as follows. A piece of slant was transferred aseptically to each sterile Erlenmeyer flask containing 100 ml of ASW. The Erlenmeyer flasks were maintained in a controlled growth room on shaker with light supplied from above by fluorescent lighting of about 90 µEm-2s-1 intensity, at a temperature of 25±3°C. After 7-10 days, the volume of each Erlenmeyer flask was transferred to a glass column. The columns were maintained under light supplied from the side at an intensity of 150 µEm-2s-1. The cultures were mixed with air containing 1-3% CO2 at a flow rate of 2 liters per minute. After 3-6 days when the culture had reached 20-50×106 cells/ml, the entire volume of each column was transferred to a polyethylene sleeve. Each sleeve was filled to a final volume of 3.0 liters of culture containing 5-8×106 cells/ml. The sleeves were maintained under light supplied from the side at an intensity of 150 µEm-2s-1. The cultures were mixed with air containing 1-3% CO2 at a flow rate of 2 liters per minute. The logarithmic phase of growth was followed by the stationary phase during which the polysaccharide accumulated in the growth medium. After 15-20 days, the polysaccharide was harvested from the enriched medium.
- The cells of the red microalgae are encapsulated within a sulfated polysaccharide, the external part of which dissolves in the medium. When the algae are grown in a liquid medium, the viscosity of the medium increases due to the dissolution of the polysaccharide from the cell surface. The entire volume of the culture in the sleeves, as obtained above, was transferred to a large vessel. The cells were separated from the supernatant using a continuous centrifugation (Cepa Z-41 20,000 rpm), and the supernatant was collected. The polysaccharide is treated further by using cross flow filtration technology for removing salts and concentrating the polysaccharide. The final product had > 0.9%, viscosity > 1400 cP.
- The concentration of the polysaccharides was determined by taking a sample of 0.5 ml of polysaccharide solution with 9.5 ml water. Typical preparation had 0.9%-1% w/w polysaccharide with phenol sulfuric acid according to Dubois M. et al. [Anal. Chem. 28 (1956) 341-354].
- Viscosity was measured using Brookfield Digital Viscometer, model DV-II. Sample of 10 ml polysaccharide was measured in spindle no. 25, speed of 30 rpm, and at room temperature.
- The polysaccharide has been tested for toxicity (irritation of the eyes) and was found to be safe for use on animals (Harlan Biotech Israel).
- An anterior cruciate ligament (ACL) resection animal model for the induction of experimental osteoarthritis in rabbits was used. Briefly, after anesthetization and preparation of two knees, the skin was incised longitudinally for approximately 3 cm medial to the patellar tendon. After opening the joint capsule, the ACL was resected macroscopically. Instability was confirmed manually by performing the anterior drawer sign test. The joint space was flushed with saline and closed with sutures. The animals received post-operative analgesics.
- Algal polysaccharide and a commercially available hyaluronan were used as viscosupplement in rabbit model. Algal polysaccharide 1% w/w in saline solution, pH 6.5-7.5 was prepared as described above, hyaluronan was obtained 1% w/w, both preparations were sterile. Six rabbits were treated as described above. Beginning one week after the resection ACL, intra-articular injections were given once a week for three consecutive weeks as follows: one knee was injected with hyaluronan preparation (0.1 cc), while the other knee was injected with algal polysaccharide (0.1 cc). Three rabbits were sacrificed at 6 weeks, the remaining animals were sacrificed after 12 weeks. The knee joints were dissected and subjected to histopathological examination according to the modified Mankin criteria [Clinical Orthopedic Research 298 (1994) 296-304]. The degenerative changes were more marked in the knees treated with the control material.
- The study population comprised 22 healthy female Awassi sheep aged two years. Osteoarthritis was induced by performing a lateral menisectomy under general anesthesia in both stifle joints of each animal. The sheep were allowed to roam free during the first 16 weeks after the surgery, with free access to food and water. By 16 weeks, all the animals walked with a limp. At 16 weeks, the sheep were given intraarticular injections of a microalgal polysaccharide or Arthrease according to the following protocol:
Table 2. Study protocol Group number Right knee Left knee 1 (8 animals) Polysaccharide single injection Saline 2 (7 animals) Polysaccharide single injection Arthrease single injection
once a week for three weeks3 (7 animals) Polysaccharide single injection Arthrease single injection
once a week for three weeksonce a week for three weeks - For the injections, each joint was accessed by a median approach. The procedure was performed under general anesthesia in an operating room. Following the injections, the sheep were returned to the farm until the end of the study, which lasted for a total of 36 weeks. At the end of that time, the animals were killed, and their knees were dissected. Upon dissection, the knees were assessed by a cartilage-damage grading system, which grades articular cartilage from 0 (normal cartilage), through various stages of damage to 5 (loss of cartilage and exposed bone). After dissection and gross evaluation of the knees, the joint surfaces were decalcified, and two slides were prepared from each joint surface. The slides were stained with hematoxylin & eosin and graded according to an adapted Mankin score, which evaluates cartilage damage.
- Matched analysis was performed on each group separately, comparing the right stifle joint to the left. Gross observation showed that the overall score was better for the knees treated with polysaccharide in groups 2 and 3 than in the matched knees treated with three injections of Arthrease, but there were no statistically significant differences among the groups. To evaluate the influence of the polysaccharide and Arthrease on the less severely damaged joints, the evaluation was repeated, with matched analysis, excluding the specimens graded as grades 4 and 5. Again, no statistically significant differences were found among the groups. Unmatched analysis compared a single injection or three injections of polysaccharide with the subgroup of animals receiving three Arthrease injections (groups 2 and 3). Gross observation showed that the overall score for joints treated with three injections of Arthrease (groups 2 and 3) was higher (i.e., worse) than that for the joints treated with polysaccharide injections (groups 2 and 3), Again, no statistically significant differences were was found.
- Matched analysis was performed on each group separately, in which the right stifle joint was compared to the left. The overall score was better for the knees treated with polysaccharide in group 2 compared with the matched knees treated with three injections of Arthrease. Groups 1 and 3 showed slightly better averages in the left stifle joints than the right stifle joints, which had been treated with polysaccharide. No statistically significant differences were found among the groups. Unmatched analysis compared joints treated with a single injection of polysaccharide with those treated with three injections of Arthrease (groups 1 and 2 right vs. groups 2 and 3 left). The overall score for the knees treated with polysaccharide was lower (i.e., better) than for the knees treated with Arthrease, although no statistically significant differences were found. To evaluate the influence of the polysaccharide and Arthrease on less severely damaged joints, the evaluation was repeated with the exclusion of the specimens graded as grades 4 and 5. Unmatched analysis showed that the overall score for the knees treated with polysaccharide was lower (i.e., better) than for knees treated with Arthrease, although no statistically significant differences were found.
- The Porphyridium sp polysaccharide was resistant toward hyaluronidase in vitro. 1ml of 0.02% wt% substrate (either hyaluronic acid or algal polysaccharide) in 0.1M phosphate buffer containing 0.15M sodium chloride, pH 5.45, was placed into Oswald viscometer, in bath thermostat at 37°C. After 5 min of incubation, the mammalian hyluronidase (Sigma, H-4272) in the same buffer solution (concentration 0.2 mg/ml) was added into the viscometer, and the count of reaction time started. The time of outflow of the reaction mixture from reservoir of viscometer was determined for reaction times 4, 8, 15, 20 and 30 min. Whereas the viscosity of hyaluronic acid was continually decreasing, the viscosity of the algal polysaccharide remained essentially unchanged.
Claims (14)
- A viscosupplement composition for use for injecting into a joint, containing a polysaccharide from a red microalga, wherein said red microalga is of the genus Porphyridium.
- A composition according to claim 1, comprising the algal polysaccharide in an aqueous solution in a concentration of from 0.5 to 2 %w/w, and having a viscosity of 500 to 8,000 cP at room temperature.
- A composition according to claim 1, wherein the polysaccharide is resistant to hyaluronidase in vitro.
- A composition according to claim 1, further comprising at least one analgesic agent, anti-inflammatory agent, antimicrobial agent, antioxidant agent, antiviral agent, anesthetic, muscle relaxant, salts, buffers, and/or diluents.
- A composition according to claim 1, further comprising a medicament needed for treating a concurrent disorder, said medicament being chosen from antibiotic, antimycotic, corticoid, antiallergic, or antineoplastic.
- A composition according to claim 1, which is non-immunogenic and nontoxic.
- Use of a polysaccharide from a red microlaga of the genus Porphyridium in the preparation of a viscosupplement composition for treating a joint disorder.
- Use according to claim 7, wherein said disorder is selected from arthritis, gout, trauma, and degeneration.
- Use according to claim 8, wherein said arthritis is osteoarthritis or rheumatoid arthritis.
- Use according to claim 7, comprising injecting the composition into a joint.
- Use according to claim 10, wherein said joint is selected from knee, hip, shoulder, ankle, elbow, spinal facet joint, and knuckle.
- Use according to claim 10, wherein said composition is injected in a volume of from 0.3 to 3 ml.
- Use according to claim 10, wherein said composition is injected either in one portion or repeatedly.
- A a viscosupplement composition for use as in claim 1 contained in a kit comprising a sterile equipment for injecting fluids into a joint, and supplier's instructions.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL172477A IL172477A (en) | 2005-12-08 | 2005-12-08 | Viscosupplementation with algal polysaccharides in the treatment of arthritis |
PCT/IL2006/001412 WO2007066340A1 (en) | 2005-12-08 | 2006-12-07 | Viscosupplementation with algal polysaccharides in the treatment of arthritis |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1957088A1 EP1957088A1 (en) | 2008-08-20 |
EP1957088B1 true EP1957088B1 (en) | 2010-11-03 |
Family
ID=37745922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06821630A Not-in-force EP1957088B1 (en) | 2005-12-08 | 2006-12-07 | Viscosupplementation with algal polysaccharides in the treatment of arthritis |
Country Status (7)
Country | Link |
---|---|
US (1) | US9119870B2 (en) |
EP (1) | EP1957088B1 (en) |
AT (1) | ATE486607T1 (en) |
DE (1) | DE602006018058D1 (en) |
ES (1) | ES2361024T3 (en) |
IL (1) | IL172477A (en) |
WO (1) | WO2007066340A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10238450B2 (en) | 2013-11-13 | 2019-03-26 | Thixos Llc | Devices, kits and methods relating to treatment of facet joints |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8298548B2 (en) | 2007-07-18 | 2012-10-30 | Solazyme, Inc. | Compositions for improving the health and appearance of skin |
EP1986665B1 (en) * | 2006-01-19 | 2018-05-02 | TerraVia Holdings, Inc. | Microalgae-derived compositions for improving the health and appearance of skin |
US8277849B2 (en) | 2006-01-19 | 2012-10-02 | Solazyme, Inc. | Microalgae-derived compositions for improving the health and appearance of skin |
US8927522B2 (en) | 2008-10-14 | 2015-01-06 | Solazyme, Inc. | Microalgal polysaccharide compositions |
WO2010054322A1 (en) | 2008-11-07 | 2010-05-14 | Solazyme, Inc. | Cosmetic compositions comprising microalgal components |
ES2718275T3 (en) * | 2009-03-27 | 2019-06-28 | Algenist Holdings Inc | Microalgae polysaccharide compositions |
WO2014186395A1 (en) | 2013-05-15 | 2014-11-20 | Solazyme, Inc. | Cosmetic compositions comprising microalgal oil |
KR101833667B1 (en) * | 2017-02-14 | 2018-03-12 | 주식회사씨에스텍 | Protection of articular cartilage composition containing Codium fragile extracts as an active ingredient |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4281061A (en) * | 1979-07-27 | 1981-07-28 | Syva Company | Double antibody for enhanced sensitivity in immunoassay |
US5910512A (en) * | 1994-04-18 | 1999-06-08 | Healthline Laboratories, Inc. | Topical analgesic using water soluble capsaicin |
US5612321A (en) * | 1995-06-22 | 1997-03-18 | Hercules Incorporated | Antioxidant grafted polysaccharides |
CA2249103A1 (en) | 1997-10-27 | 1999-04-27 | Samir S. Badour | Novel hyaluronic acid produced from algae |
JP3573941B2 (en) * | 1998-02-13 | 2004-10-06 | マイクロアルジェコーポレーション株式会社 | Composition having hyaluronidase inhibitory activity and cosmetic containing the composition |
FR2785909A1 (en) * | 1998-11-16 | 2000-05-19 | Aquamer | Microalgal culture extract with superoxide dismutase-like activity useful for preparing cosmetic, dietetic, pharmaceutical and veterinary products for preventing or treating aging and degeneration |
SE0001631D0 (en) | 2000-05-04 | 2000-05-04 | Sahltech Ab | New use |
US20050196410A1 (en) * | 2004-03-05 | 2005-09-08 | Daniels Bruce A. | Seaweed extract composition for treatment of inflammation |
-
2005
- 2005-12-08 IL IL172477A patent/IL172477A/en not_active IP Right Cessation
-
2006
- 2006-12-07 EP EP06821630A patent/EP1957088B1/en not_active Not-in-force
- 2006-12-07 ES ES06821630T patent/ES2361024T3/en active Active
- 2006-12-07 AT AT06821630T patent/ATE486607T1/en not_active IP Right Cessation
- 2006-12-07 DE DE602006018058T patent/DE602006018058D1/en active Active
- 2006-12-07 US US12/096,290 patent/US9119870B2/en not_active Expired - Fee Related
- 2006-12-07 WO PCT/IL2006/001412 patent/WO2007066340A1/en active Application Filing
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10238450B2 (en) | 2013-11-13 | 2019-03-26 | Thixos Llc | Devices, kits and methods relating to treatment of facet joints |
Also Published As
Publication number | Publication date |
---|---|
US20090017058A1 (en) | 2009-01-15 |
IL172477A0 (en) | 2006-04-10 |
WO2007066340A1 (en) | 2007-06-14 |
DE602006018058D1 (en) | 2010-12-16 |
US9119870B2 (en) | 2015-09-01 |
ATE486607T1 (en) | 2010-11-15 |
IL172477A (en) | 2012-06-28 |
ES2361024T3 (en) | 2011-06-13 |
EP1957088A1 (en) | 2008-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1957088B1 (en) | Viscosupplementation with algal polysaccharides in the treatment of arthritis | |
US5925626A (en) | Hyaluronic acid fractions having pharmaceutical activity, and pharmaceutical compositions containing the same | |
KR101419961B1 (en) | Treatment of cartilage disorders with FGF-18 | |
CN102630157B (en) | Injectable compositions for intra-articular use combining a viscosupplementation agent and a fibroblast growth medium | |
US20070197471A1 (en) | Treatment of degenerative cartilage conditions in a mammal with Glycosidasc Inhibitors | |
JP2008531148A (en) | Amide derivatives of hyaluronic acid in osteoarthritis | |
CN105106238A (en) | Cell therapy composition for treating osteoarthritis and cartilage defects | |
CN104321064A (en) | Chondroitin for use in medicine | |
US7763594B2 (en) | Compositions for the treatment of osteoarthritis and to nourish the synovial fluid | |
Abdou et al. | Fusogens: Chemical agents that can rapidly restore function after nerve injury | |
ES2281265B1 (en) | COMPOSITIONS FOR THE TREATMENT OF ARTROSIS. | |
EP0820293A1 (en) | Bioactive concentrate, its producing method and certain drug compositions containing also chondroitin sulphate | |
US11685760B2 (en) | Amino acid derivative of glucosamine stimulating extracellular matrix synthesis and pharmaceutical composition comprising the same | |
EP4008308A1 (en) | Composition comprising hyaluronic acid and pluronic for preventing or treating articular and cartilage injury | |
JP2007507516A (en) | Treatment of mammalian disorders by amino sugar administration and use of amino sugar | |
JP4461286B2 (en) | Chondrocyte proliferation promoter and cartilage disorder preventive or therapeutic agent | |
IL257492A (en) | Compositions comprising fgf-18 | |
WO2023074893A1 (en) | Cartilage regeneration composition | |
Karaduman et al. | Chondroprotective efficiencies of intra-articular treatment of glucosamine sulfate and hyaluronic acid | |
ES2304886B1 (en) | "COMPOSITIONS TO NUTRIR THE ARTICULATIONS". | |
US9095551B2 (en) | Combined preparation for treating joint diseases | |
CN117180304A (en) | Hyaluronic acid mucopolysaccharide composite solution, preparation method and application thereof | |
CN116983407A (en) | New generation stem cell therapeutic agent for treating knee arthritis and preparation process thereof | |
Kanemitsu et al. | 33 Potential Health Benefits of Orally Administered Hyaluronan in Alleviating Knee Joint Pain | |
EP1143793A1 (en) | Organoprotective solutions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080605 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20091027 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 602006018058 Country of ref document: DE Date of ref document: 20101216 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20101103 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20101103 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101103 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101103 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110303 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101103 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110303 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101103 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101103 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101103 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110203 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101103 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2361024 Country of ref document: ES Kind code of ref document: T3 Effective date: 20110613 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110204 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101103 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101103 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101103 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20101231 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101103 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101103 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101103 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101103 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20110804 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20101231 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20101207 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20101231 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602006018058 Country of ref document: DE Effective date: 20110804 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101103 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20101207 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110504 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101103 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20161228 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20161222 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20170228 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20170127 Year of fee payment: 11 Ref country code: IT Payment date: 20161223 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602006018058 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20171207 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20180831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171207 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180703 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180102 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171207 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20190702 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171208 |